The KN-412 trial similarly included patients with PD-L1-negative and HPV-associated HNSCC, here adding the validated PD-1 inhibitor pembrolizumab to radiation and concurrent high-dose cisplatin. Here, CD274 is linked to head and neck squamous cell carcinoma.